Baseline demographic and clinical features of patients.
| Characteristic | |
|---|---|
| Sex, men:women | 5:7 |
| Age, mean ± SD yrs | 53.00 ± 11.69 |
| Diagnosis | |
| Rheumatoid arthritis | 5 |
| Psoriatic arthritis | 5 |
| Seronegative arthritis | 1 |
| Entero-spondyloarthropathy | 1 |
| Disease duration, mean ± SD 101.67 ± 63.40 months (range 23 to 226) | |
| Previous therapies*, no. patients | |
| Methotrexate | 9 |
| Cyclosporine | 6 |
| Sulfasalazine | 4 |
| Hydroxychloroquine | 4 |
| Leflunomide | 3 |
| Gold salts | 2 |
| Anti-TNF treatment duration, mean ± SD 41.08 ± 33.93 months (range 9 to 104) | |
| Type of TNF inhibitor, no. patients | |
| Etanercept | 7 |
| Adalimumab | 5 |
| Concomitant DMARD, no. patients | |
| Methotrexate | 3 |
| Sulfasalazine | 1 |
↵* Since some patients were treated with more than one agent, the cumulative number exceeds 100%. TNF: tumor necrosis factor; DMARD: disease modifying antirheumatic drug.